Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer

International Journal of Cancer

Volumn 131, Issue 4, 2012, Pages

  McCawley, Niamh ^a,b   Conlon, Susan ^b   Hector, Suzanne ^a   Cummins, Robert J ^b   Dicker, Patrick ^a   Johnston, Patrick G ^c   Kay, Elaine W ^b   McNamara, Deborah A ^b   Prehn, Jochen H M ^a   Concannon, Caoimhín G ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b BEAUMONT HOSPITAL   (Ireland)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

colon cancer; proteasome; Rpt4; tissue array

Indexed keywords

20S PROTEASOME CORE; CORE PROTEIN; FLUOROURACIL; PROTEASOME; PROTEIN RPT4; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 84860248725     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26468     Document Type: Article

References (25)

1. Parkin DM, Bray F, Ferlay J, Pisani P,. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
2. Johnston PG,. The colorectal cancer coalition: reflections on the future. Oncologist 2006; 11: 970-2. (Pubitemid 44564803)
3. Labianca R, Nordlinger B, Beretta GD, Brouquet A, Cervantes A,. Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v70-7.
4. Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-51. (Pubitemid 38702845)
5. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR,. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30. (Pubitemid 41095110)
6. Andre T, Sargent D, Tabernero J, O'Connell M, Buyse M, Sobrero A, Misset JL, Boni C, de Gramont A,. Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 2006; 13: 887-98. (Pubitemid 43727375)
7. Kohne CH,. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal. Lancet Oncol 2006; 7: 516-7.
8. Sobrero A,. Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal. Lancet Oncol 2006; 7: 515-6.
9. Ciechanover A,. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998; 17: 7151-60. (Pubitemid 29002684)
10. Peters JM, Cejka Z, Harris JR, Kleinschmidt JA, Baumeister W,. Structural features of the 26 S proteasome complex. J Mol Biol 1993; 234: 932-7. (Pubitemid 24027223)
11. Brooks P, Fuertes G, Murray RZ, Bose S, Knecht E, Rechsteiner MC, Hendil KB, Tanaka K, Dyson J, Rivett J,. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem J 2000; 346 (Pt 1): 155-61. (Pubitemid 30113832)
12. Hoeller D, Hecker CM, Dikic I,. Ubiquitin and ubiquitin-like proteins in cancer pathogenesis. Nat Rev Cancer 2006; 6: 776-88. (Pubitemid 44450466)
13. Eldridge AG, O'Brien T,. Therapeutic strategies within the ubiquitin proteasome system. Cell Death Differ 2009; 17: 4-13.
14. Adams J,. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7: 9-16. (Pubitemid 34151104)
15. Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih Ie M, Roden RB,. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006; 66: 3754-63.
16. Chen L, Madura K,. Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue. Cancer Res 2005; 65: 5599-606. (Pubitemid 40911160)
17. McDermott U, Boyd, RE, Houston, RF,. A phase III trial of short duration adjuvant chemotherapy with bolus/infusional 5-fluorouracil and folinic acid versus surgery alone in Dukes' B and C colorectal cancer. Proc Am Soc Clin Oncol 2003; 22.
18. McLornan DP, Barrett HL, Cummins R, McDermott U, McDowell C, Conlon SJ, Coyle VM, Van Schaeybroeck S, Wilson R, Kay EW, Longley DB, Johnston PG,. Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer. Clin Cancer Res 2010; 16: 3442-51.
19. O'Connell JB, Maggard MA, Ko CY,. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-5. (Pubitemid 39429665)
20. Tanaka K, Yoshimura T, Tamura T, Fujiwara T, Kumatori A, Ichihara A,. Possible mechanism of nuclear translocation of proteasomes. FEBS Lett 1990; 271: 41-6. (Pubitemid 20336200)
21. Scabini S,. Sentinel node biopsy in colorectal cancer: must we believe it? World J Gastrointest Surg 2010; 2: 6-8.
22. Voutsadakis IA,. Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin-proteasome system and Cox-2. J Cell Mol Med 2007; 11: 252-85. (Pubitemid 46695694)
23. Funakoshi M, Tomko RJ, Jr., Kobayashi H, Hochstrasser M,. Multiple assembly chaperones govern biogenesis of the proteasome regulatory particle base. Cell 2009; 137: 887-99.
24. Kaneko T, Hamazaki J, Iemura S, Sasaki K, Furuyama K, Natsume T, Tanaka K, Murata S,. Assembly pathway of the Mammalian proteasome base subcomplex is mediated by multiple specific chaperones. Cell 2009; 137: 914-25.
25. Yan DW, Li DW, Yang YX, Xia J, Wang XL, Zhou CZ, Fan JW, Wen YG, Sun HC, Wang Q, Qiu GQ, Tang HM, et al. Ubiquitin D is correlated with colon cancer progression and predicts recurrence for stage II-III disease after curative surgery. Br J Cancer 2010; 103: 961-9.